Derek Chalmers is the President and Chief Executive Officer at Oban and also serves on the company’s board of directors. Dr. Chalmers has greater than 27 years' experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding Oban Biopharma, Dr. Chalmers co-founded Cara Therapeutics (NASDAQ: CARA) and served as Director, CEO and President from inception in July,2004 through November,2021. During his tenure he oversaw the development and regulatory approval of KORSUVATM, the first non-scheduled kappa opioid agonist approved by the FDA and negotiated and consummated corporate license agreements with Johnson & Johnson, Vifor Pharma (CSL Pharma), Maruishi Pharmaceuticals and Kun Dang Pharmaceutical Corporation. Prior to Cara, Dr. Chalmers co-founded Arena Pharmaceuticals (Acquired by Pfizer in 2022), a drug discovery and development company focused on novel GPCR targets and served as its Director and Vice President of Research and Development from inception through 2004. Prior to Arena, Dr. Chalmers was a group leader in drug discovery at Neurocrine Biosciences (NASDQ: NBIX). Dr. Chalmers holds a Ph.D. from The Wellcome Surgical Institute, University of Glasgow and has previously conducted research as both a Fogerty International Fellow and NARSAD Fellow at The University of Michigan Medical Center. Dr. Chalmers is inventor or author of greater than 100 issued patents or peer reviewed scientific papers